SGP Company Profile and Key Details

Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $62.00 to $37.00. The high target offers 129.04% upside. The low target suggests 36.68% downside. The mean target is $45.00. This offers 66.24% upside. SpyGlass Pharma, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by 14.69%. The prior quarter beat by -11.94%. Over the last six quarters, Apple has recorded several small beats. These include 896.13% in March 26, 2026.

Short-term trend indicators are mixed aligned (SMA20 0.48%, SMA50 0.48%, SMA200 0.48%). The stock remains hovering near 52-week lows, trading -12.61% below its high and over 40.63% above its low. Average 10-day trading volume of 225.13 thousand shares is significantly above the 3-month average of 111.27 thousand, indicating heightened recent market interest.

SpyGlass Pharma, Inc. Common Stock has 33.45 million shares outstanding. The public float is 6.50 million shares, elevated short interest at 10.27% of float. This equals 1.14 million shares. The short ratio is 9.81 days. Institutional investors hold 98.91% of the float. Insiders own 4.28%.

SpyGlass Pharma, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.97. This means the shares are trading above this model’s fair value.

currently trading near 52-week highs band. Valuation shows SpyGlass Pharma, Inc. Common Stock trading at a premium to the broader market with a P/E of -16.31. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $45.00, suggesting 66.24% upside. Our AI forecast model points to short-term strength (4.69% over two weeks), a medium-term rise (26.86% over three months), and a longer-term loss (-19.58% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that SpyGlass Pharma, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.69%, with price expected at $28.34 by October 09, 2026, within a range of $27.60 to $29.07 3-Month Outlook: Projected rise of 26.86%, reaching $34.34 by December 24, 2026, with a range of $34.04 to $34.64. 1-Year Outlook: Projected loss of -19.58%, with price at $21.77 by September 24, 2027, within a range of $20.90 to $22.64.

SpyGlass Pharma, Inc. Common Stock (NASDAQ:SGP) closed at $27.07 USD, losing -$0.58 (-2.10%) from the previous close of $27.65. The stock is currently mid-range between its 52-week high and low $17.06 and $32.44. With a market capitalization of about $905.04 million, SpyGlass Pharma, Inc. Common Stock is classified as a small-cap and shows lower-than-market volatility (beta ~-0.93). Key stats such as the average daily volume over the past year has been around 112.60 thousand shares, in line with its 52-week average. Headquartered in Irvine, CA, SpyGlass Pharma, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Patrick H. Mooney, the company employs approximately 76 people and listed since February 06, 2026. SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions.

SpyGlass Pharma, Inc. Common Stock trades at a P/E ratio of -16.31, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.9 trading at moderately above to book value. The P/FCF stands at -18.2, also below market averages.